Wednesday, 4 November 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

AstraZeneca AB

organization80% conf.·synced Aug 13, 2026

Pharmaceutical company with license agreement with Insmed

57
sourced metrics
409
relationships
20
stated objectives
2
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Revenue
30595USD
Jul 27, 2026source
Eps
1.61USD
Jul 27, 2026source
Dividend Per Share
1.06USD
Jul 27, 2026source
Stock Price
168.90USD
Jul 17, 2026source
Stock Return 30day
5.2percent
Apr 1, 2026source
Stock Return 1year
54.8percent
Apr 1, 2026source
Free Cash Flow
9.49USD
Apr 1, 2026source
Stock Return Ytd
12.1percent
Apr 1, 2026source
Projected Free Cash Flow
20.16USD
Apr 1, 2026source
Valuation Score
3out_of_6
Apr 1, 2026source
Intrinsic Value Dcf
238.68USD
Apr 1, 2026source
Stock Return 7day
-0.6percent
Apr 1, 2026source
Marathon Holding Value
12.85USD
Mar 31, 2026source
Marathon Holding Pct Aum
2.9percent
Mar 31, 2026source
Return 1year
21.8percent
Mar 1, 2026source
Analyst Price Target
165.33GBP
Mar 1, 2026source
Free Cash Flow Projected
20.2USD
Mar 1, 2026source
Intrinsic Value Per Share
242.86GBP
Mar 1, 2026source

Stated objectives

Reach $80bn in annual sales by 2030

source
target: 80 billion USD by 2030-01-01 00:00:00stated

Achieve operating margin in mid-thirties percent range

source
target: 35 percent stated

High single digit revenue growth for 2025 on constant currency basis

source
target: 7-9 percent by 2025-01-01 00:00:00stated

Low double digit growth in adjusted earnings per share for 2025 on constant currency basis

source
target: 10-12 percent by 2025-01-01 00:00:00stated

Increase total revenue by mid-to-high single-digit percentage for FY 2026 at constant exchange rates

source
target: mid-to-high single-digit percentage growth by 2026-12-31 00:00:00stated

Increase core EPS by low double-digit percentage for FY 2026 at constant exchange rates

source
target: low double-digit percentage growth by 2026-12-31 00:00:00stated

Invest $15 billion in China through 2030 to expand medicines manufacturing and R&D

source
target: $15 billion by 2030-12-31 00:00:00stated

Complete more than 20 Phase 3 trial readouts in 2026

source
target: 20+ Phase 3 readouts by 2026-12-31 00:00:00stated

Obtain FDA approval for baxdrostat as first-in-class aldosterone synthase inhibitor for hard-to-control hypertension

source
target: regulatory approval stated

Advance portfolio of medicines for organ protection by slowing or stopping disease progression, paving way towards regenerative therapies in CVRM

source
stated

Relationship graph · 409 connections

Developed by
145
Competes with
73
Employs
25
Partnered with
21
located in
13
headquartered in
12
contracted by
10
acquired by
10
Invested in
Greater China

Via News coverage

Europe's Oncology Pipeline Shift: Regulators and Dealmakers Are Rewarding New Drug Types, but Summit's Books Show the Cost
October 18, 2026
Oncology's Next Wave Meets Europe's Regulators: Summit's $1.08bn Loss, a Trodelvy Opinion and a Take-Private Deal
October 13, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Moves Into Devices, Security and Platforms: Physical AI Data, On-Device Compute and Agent Governance Drive a Late-October Product Wave
In late October 2026, vendors across hardware, enterprise software and security launched products built around AI moving out of the cloud and into devices, workflows and physical systems. Examples include NVIDIA RTX Spark laptops with Adobe, ASUS and Windows support for local and hybrid AI, and Harvest Praxis and Encord on embodied or physical AI. Enterprise software and security vendors (Salesforce–Braze, Fortinet, ServiceNow, Cisco, Intuit) are consolidating AI-driven customer data, adding inline AI security and agent governance, and embedding AI in financial and accounting workflows. The finance link is indirect: it rests on M&A, fintech-adjacent AI tooling and the capital flowing into physical AI. No regulatory driver appears in the facts.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,548 source documents archived
Query this data → isubstrate.com